DIA 2013 49th Annual Meeting
Click here to go to the previous page
Optimizing the Transition from Preclinical to Clinical Research
Track
:
Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code:
269
Date:
Tuesday, June 25, 2013
Time:
4:00 PM to 5:30 PM
EST
Location:
105
CHAIR
:
Stella Stergiopoulos, (SCHSUP), Project Manager, Tufts Center for the Study of Drug Development, United States
SPEAKER
(S):
Stella Stergiopoulos, (SPKSUP), Project Manager, Tufts Center for the Study of Drug Development, United States Laszlo Urban, MD,PhD (SPKNON), Head, Preclinical Safety Profiling, Novartis Institutes for Biomedical Research, United States Simone Braggio, DrSc (SPKNON), Director, Drug Design and Discovery, Aptuit, Italy
Description
This session will highlight strategies for transitioning from nonclinical to early phase drug discovery most efficiently. The first presentation will discuss current industry processes and perceived costs in preclinical and early phase drug development. The second presentation will focus on risk mitigation in early phase studies, while the third presentation will focus on strategies for bridging the gap between preclinical and clinical development.
This session is a part of:
This session is a part of: